Imunon Abstract On Phase 2 Study With IMNN-001 Plus Bevacizumab Accepted For Presentation At ASCO Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Imunon announced that its abstract on a Phase 2 study with IMNN-001 in combination with Bevacizumab has been accepted for presentation at the ASCO Annual Meeting.
May 15, 2024 | 12:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Imunon's abstract on a Phase 2 study with IMNN-001 in combination with Bevacizumab has been accepted for presentation at the ASCO Annual Meeting. This could increase visibility and investor interest in the company.
The acceptance of the abstract for presentation at a prestigious event like the ASCO Annual Meeting can significantly boost the company's visibility and credibility in the biotech sector. This could lead to increased investor interest and a potential short-term rise in stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100